Your browser doesn't support javascript.
loading
Advances in Alzheimer's disease's pharmacological treatment.
Conti Filho, Carlos Elias; Loss, Lairane Bridi; Marcolongo-Pereira, Clairton; Rossoni Junior, Joamyr Victor; Barcelos, Rafael Mazioli; Chiarelli-Neto, Orlando; da Silva, Bruno Spalenza; Passamani Ambrosio, Roberta; Castro, Fernanda Cristina de Abreu Quintela; Teixeira, Sarah Fernandes; Mezzomo, Nathana Jamille.
Afiliação
  • Conti Filho CE; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Loss LB; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Marcolongo-Pereira C; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Rossoni Junior JV; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Barcelos RM; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Chiarelli-Neto O; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • da Silva BS; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Passamani Ambrosio R; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Castro FCAQ; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Teixeira SF; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
  • Mezzomo NJ; Faculty of Medicine, University Center of Espirito Santo, Colatina, Brazil.
Front Pharmacol ; 14: 1101452, 2023.
Article em En | MEDLINE | ID: mdl-36817126
Alzheimer's disease (AD) is the most common type of dementia in the elderly. Several hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal protective or regenerative drug is available nowadays. Researchers still work in drug development and are finding new molecular targets to treat AD. Therefore, this study aimed to summarize main advances in AD pharmacological therapy. Clinical trials registered in the National Library of Medicine database were selected and analyzed accordingly to molecular targets, therapeutic effects, and safety profile. The most common outcome was the lack of efficacy. Only seven trials concluded that tested drugs were safe and induced any kind of therapeutic improvement. Three works showed therapeutic effects followed by toxicity. In addition to aducanumab recent FDA approval, antibodies against amyloid-ß (Aß) showed no noteworthy results. 5-HT6 antagonists, tau inhibitors and nicotinic agonists' data were discouraging. However, anti-Aß vaccine, BACE inhibitor and anti-neuroinflammation drugs showed promising results.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça